Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Alembic Pharmaceuticals Limited is a vertically integrated Indian pharmaceutical company making and marketing generic formulations, APIs and branded generics in India while exporting to the U.S., Europe, ROW and country subsidiaries, with USFDA‑approved manufacturing and a significant ANDA pipeline (cumulative 270 filings and 212 cumulative final approvals).
Q3 FY26 revenue grew 11% year‑on‑year to INR 1,876 crore, with gross margin of 72% and EBITDA before R&D at 25% of revenue; PAT before exceptional items rose 21% year‑on‑year to INR 168 crore, showing resilient operating leverage despite U.S. pricing pressure and higher R&D spend.
R&D intensity is high—around 8–9% of revenue with quarterly R&D at INR 165 crore and full‑year guidance of INR 600–650 crore—supporting a strategy focused on complex injectables, ophthalmics, peptides and early‑entry ANDA opportunities including First‑to‑File and differentiated launches.
Geographic diversification is advancing: U.S. grew modestly (6% in Q3) while EROW expanded 36% by region, API and Pfizer collaborations showing variable performance; management expects U.S. mid‑teens potential over coming years and aims to commercialize its first U.S. branded product (Pivya) in Q4 FY26.
Pharmaceuticals & Biotechnology
Pharmaceuticals
16,099 Cr
Moderate Risk
23.9
37.2
1.1
2.8
1,024.70
635.30
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Alembic Pharmaceuticals Ltd (APLLTD) is currently trading at 819.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Alembic Pharmaceuticals Limited is a vertically integrated Indian pharmaceutical company making and marketing generic formulations, APIs and branded generics in India while exporting to the U.S., Europe, ROW and country subsidiaries, with USFDA‑approved manufacturing and a significant ANDA pipeline (cumulative 270 filings and 212 cumulative final approvals). Q3 FY26 revenue grew 11% year‑on‑year to INR 1,876 crore, with gross margin of 72% and EBITDA before R&D at 25% of revenue; PAT before exceptional items rose 21% year‑on‑year to INR 168 crore, showing resilient operating leverage despite U.S. pricing pressure and higher R&D spend. R&D intensity is high—around 8–9% of revenue with quarterly R&D at INR 165 crore and full‑year guidance of INR 600–650 crore—supporting a strategy focused on complex injectables, ophthalmics, peptides and early‑entry ANDA opportunities including First‑to‑File and differentiated launches. Geographic diversification is advancing: U.S. grew modestly (6% in Q3) while EROW expanded 36% by region, API and Pfizer collaborations showing variable performance; management expects U.S. mid‑teens potential over coming years and aims to commercialize its first U.S. branded product (Pivya) in Q4 FY26.
Over the past 52 weeks, Alembic Pharmaceuticals Ltd has traded between a low of ₹635.30 and a high of ₹1,024.70. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Alembic Pharmaceuticals Ltd has a market capitalization of approximately 16,009.08. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Alembic Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 23.73 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 16,009.08 Cr, Alembic Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Alembic Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Alembic Pharmaceuticals Ltd is 23.73. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The USFDA completed a cGMP inspection at Alembic’s Karakhadi facility (Feb 9-18, 2026) and issued a Form 483 with two observations.
Alembic Pharmaceuticals said it received final USFDA approval for its ANDA for Dapsone Gel, 5%.
Alembic received final USFDA approval for its ANDA for Oseltamivir Phosphate for Oral Suspension, 6 mg/mL.
Alembic received USFDA final approval for its generic oseltamivir phosphate for oral suspension, 6 mg/ml, for the treatment of influenza.
Discovery themes featuring this stock
Bearish
2
Neutral
8
Bullish
4
Bearish
9
Neutral
8
Bullish
29
Bearish
7
Neutral
0
Bullish
25
Product/Operations Update
Alembic Pharmaceuticals Ltd received USFDA final approval for Prucalopride Tablets 1 mg and 2 mg (ANDA), RLD Motegrity; estimated market ~US$100M (12 months to Mar 2026); Alembic has 245 ANDA approvals.
Earnings Call/Transcript
Alembic Pharmaceuticals will hold a post-results conference call to discuss Q1 FY27 unaudited financial results on 2026-08-04 at 17:30 IST for analysts and institutional investors.
Earnings Call/Transcript
Alembic Pharmaceuticals intimation for a post-results conference call to discuss Q1 FY27 unaudited financial results on 2026-08-04 at 17:30 IST for analysts and institutional investors.
Board Meeting
Alembic Pharmaceuticals will hold a Board meeting on 2026-08-04 to consider and approve unaudited financial results for the quarter ended 30 June 2026; trading window closed from 2026-07-01 will reopen 48 hours after declaration.
Board Meeting
Alembic Pharmaceuticals Ltd informed exchanges that its Board will meet on 2026-08-04 to consider and approve unaudited financial results for the quarter ended 30 June 2026; trading window to reopen 48 hours after results.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
925.25 | 16,606 Cr | 11.71 | 1.80 | 0.54 | 15.38 | 15.37 | 12.39 | ||
426.45 | 16,443 Cr | 91.74 | 4.20 | 0.00 | 5.05 | 5.47 | 2.62 | ||
814.90 | 16,009 Cr | 23.73 | 2.82 | 1.47 | 11.89 | 10.81 | 7.66 | ||
975.00 | 15,584 Cr | 39.11 | 2.20 | 0.51 | 5.62 | 6.41 | 2.56 | ||
1134.25 | 13,876 Cr | 24.58 | 4.16 | 0.44 | 16.94 | 22.33 | 14.17 | ||
1260.00 | 13,150 Cr | 50.40 | 6.52 | 0.60 | 12.94 | 17.08 | 11.60 | ||
2101.90 | 12,807 Cr | 69.18 | 17.15 | 0.48 | 24.79 | 27.13 | 15.36 | ||
| Median: 7 Co. | — | 975.00 | 15,584 Cr | 39.11 | 4.16 | 0.51 | 12.94 | 15.37 | 11.60 |
